Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
12:51pm, Tuesday, 02'nd Jun 2026
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
08:00am, Friday, 29'th May 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
12:00pm, Wednesday, 27'th May 2026
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
NPCE Explains How NeuroPace's RNS System Makes Money
11:46am, Wednesday, 27'th May 2026
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
11:36am, Wednesday, 27'th May 2026
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
01:25pm, Wednesday, 13'th May 2026
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
10:10pm, Tuesday, 12'th May 2026
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
NeuroPace Q1 Earnings Call Highlights
09:09pm, Tuesday, 12'th May 2026
NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution acros
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Tuesday, 12'th May 2026
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.21 per share a year ago.
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
04:05pm, Tuesday, 12'th May 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
10:36am, Thursday, 07'th May 2026
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a majo
NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Survey
02:14am, Friday, 24'th Apr 2026
NeuroPace (NASDAQ: NPCE - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the tw
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Friday, 10'th Apr 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
